% | $
Quotes you view appear here for quick access.


  • alexalekhine alexalekhine Nov 17, 2010 8:06 PM Flag

    OT: RDEA

    According to Kim Lee at RDEA's "Study 111" demonstrated reduction of serum uric acid levels below 4mg/dL in 100% of patients when RDEA 594 was used in combination with Allopurinol at the highest dose tested.

    The data was disclosed at the recent ACR meeting where SVNT presented additional OLE data on "K."


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • rdea is years from fda review

      • 1 Reply to ggg71121
      • In several large studies both Allop and Febux had about 2% of patients allergic to the drug. These patients will likely never be able to go on the combo treatment w/RDEA. Again,like the HIV/AIDS mkt,the gout mkt is so big and growing there will be ample patients for all entrants to make good money. Patients respond differently to all drugs. SVNT only has to capture 1% of the total world gout mkt(10M patients ?)....100k TFG make meaningful revs and profits @ $20k/yr/pp or higher. That has always been the play and nothing will change that until we see another gout drug drop uric acid levels to under 1 in 24 hours like K does. K is the tophi buster and as Decision Resources' 90 surveyed rheumatolopgists said, will be the "gold standard" in gout by 2013-2018.

    • "Demonstrated Reduction" - does not say how much or whether it is more (or does a better job) than SVNT's K.

      "4mg" - SVNT's K is vetted to work with more severe cases, so it seems that these drugs are not exactly going head to head.

      • 1 Reply to chimpfighter
      • Actually, it DOES say how much and how frequently.

        In 100% of the patients teseted, the serum uric acid level fell below 4mg/dL.

        The clinical measure for Krystexxa in its clinical trial was reduction below 6mg/dL.

        Thus, your statement is inaccurate.

        There also is a dramatic difference bwetween a pill (RDEA) and an bi-weekly infusion in terms of risks (anaphylaxsis) and costs.

        Get a clue.

        The buyers are not looking at how much will revenue be in 2011/2012.

        They are looking at what will the revenue be 5 years out and beyond.

        THAT is the problem here.

        As for going head-to-head, if RDEA keeps uric acid low, then severe cases will never develop to the stage where they need K.


    • Obviously I'm not a doctor, not in the field nore a patient but is this latest RDEA study findings valid enough to take the wind from SVNT's K sails for good? And does anyone here think this might be the biggest reason SVNT has dropped so much and staying down now?

    • Do you know how RDEA594 impacts K's orphan drug designation?